Apalutamide

Target: This ligand targets the androgen receptor (AR) ligand-binding domain in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for the androgen receptor (AR) ligand-binding domain. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings the androgen receptor (AR) ligand-binding domain into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• Androgen Receptor PROTAC Development: Apalutamide can be repurposed as an androgen receptor (AR)-binding ligand within PROTAC constructs to recruit E3 ligases and drive AR ubiquitination. This enables systematic evaluation of AR degradation efficiency, degradation kinetics, and dependence on AR expression level across prostate cancer models and engineered cell lines.

• AR Degradation Mechanism Studies: Using apalutamide-based PROTACs supports mechanistic dissection of AR turnover pathways, including ubiquitin linkage preferences, proteasome dependence, and lysosomal contribution. Researchers can compare degradation versus inhibition phenotypes to clarify whether reduced signaling arises primarily from protein removal or from residual receptor antagonism.

• Resistance-Associated Variant Targeting: Apalutamide-derived targeting moieties can be applied to test PROTAC activity against AR variants linked to therapy resistance. By constructing PROTACs that maintain strong AR engagement while recruiting distinct E3 ligases, investigators can map how mutations affect ternary complex formation and degradation potency.

• E3 Ligase Recruitment Optimization: Apalutamide-based PROTACs are well suited for screening E3 ligase recruiters to identify configurations that maximize AR degradation. Systematic variation of linker length, recruiter identity, and binding geometry can reveal design rules governing ternary complex stability and overall degradation magnitude.

• Signal Pathway Downstream Profiling: Apalutamide-targeted PROTACs can be used to study how AR degradation reshapes downstream transcriptional programs. By coupling degradation readouts with AR target gene expression and phenotypic assays, researchers can quantify the relationship between AR depletion depth, duration, and suppression of androgen-responsive signaling.

Apalutamide is a androgen receptor ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of Apalutamide is characterized by amide/urea/sulfonamide hydrogen-bonding motifs; halogenated aryl/heteroaryl ring system; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The sulfur-containing handle can be considered for thioether, disulfide, or maleimide-compatible linker installation if the binding epitope tolerates substitution. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.